Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R21)

Key Dates: 
  • Posted Date: May 17, 2017
  • Open Date (Earliest Submission Date): August, 7, 2017
  • Letter of Intent Due Date(s): Not Applicable
  • Application Due Date(s): Standard AIDS dates apply , by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: Standard dates apply
  • Advisory Council Review: Standard dates apply
  • Earliest Start Date: Standard dates apply
Purpose: 

The purpose of this Funding Opportunity is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between minority variants and treatment outcomes and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

Expiration Date: 
Friday, May 8, 2020
Announcement Number: 
PA-17-292